top
Search terms
Results 1 - 8 of 8 - ordered by :
Ehjcvp

Introduction Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a P2Y12 inhibitor, is recommended by guidelines for up to 12 months in patients with acute coronary ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Articles, Gianluigi Savarese, Stefano Savonitto, Lars H. Lund, Stefania Paolillo, Caterina Marciano, Santo Dellegrottaglie, Antonio ...

Date : 01/10/2016 Item size : 333679 bytes
Ehjcvp

Atrial fibrillationIschaemic strokePreventionOral anticoagulationIntroduction Atrial fibrillation (AF) is an expanding epidemic,1 and ischaemic stroke due to cardioembolism remains a trademark ...

European Heart Journal - Cardiovascular Pharmacotherapy, Current Opinion, Thure Filskov Overvad, Peter Brønnum Nielsen, Gregory Y. H. Lip

Date : 12/08/2016 Item size : 256208 bytes
Ehjcvp

Atrial fibrillationIschaemic strokePreventionOral anticoagulationIntroduction Atrial fibrillation (AF) is an expanding epidemic,1 and ischaemic stroke due to cardioembolism remains a trademark ...

European Heart Journal - Cardiovascular Pharmacotherapy, Current Opinion, Thure Filskov Overvad, Peter Brønnum Nielsen, Gregory Y. H. Lip

Date : 01/01/2017 Item size : 256149 bytes
Ehjcvp

Glycoprotein IIb/IIIa receptor inhibitors (GPIs) block the final common pathway leading to platelet aggregation that occurs via the cross-linking of fibrinogen and von Willebrand factor upon exposure ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Jeffrey D. Wessler, Robert P. Giugliano

Date : 01/04/2015
Ehjcvp

The aim of this review is to provide an overview of the evidence from randomized, clinical trials and epidemiological studies, with a focus on the optimal duration of dual antiplatelet therapy (DAPT) ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Pierre Sabouret, Sophie K. Rushton-Smith, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Gilles Montalescot

Date : 01/07/2015
Ehjcvp

Due to the introduction of foreign materials to the circulation (either temporarily or permanently) and due to a certain damage to the endothelium or endocardium, the risk of thrombotic complications ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, P. Widimský, V. Kočka, F. Roháč, P. Osmančík

Date : 01/04/2016
Ehjcvp

In patients without left ventricular dysfunction and/or overt HF, three large studies (Heart Outcomes Prevention Evaluation, HOPE trial,3 the European trial on Reduction Of cardiac events with ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Stefania Paolillo, Pasquale Perrone Filardi

Date : 01/04/2015
Ehjcvp

Introduction Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a P2Y12 inhibitor, is recommended by guidelines for up to 12 months in patients with acute coronary ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLE, Gianluigi Savarese, Stefano Savonitto, Lars H. Lund, Stefania Paolillo, Caterina Marciano, Santo Dellegrottaglie, Antonio ...

Date : 21/04/2016